Gene · 774
CACNA1B: calcium voltage-gated channel subunit alpha1 B
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CACNA1B: calcium voltage-gated channel subunit alpha1 B. Genes, record 774. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/774
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q00975 | Voltage-dependent N-type calcium channel subunit alpha-1B | 2,339 | 7 | Ensembl, GeneID, HGNC |
Source UniProt
Patents43
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 39659 | Q00975 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9190 | Q00975 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 688 | Q00975 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 688 | Q00975 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9190 | Q00975 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 10765 | Q00975 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 25477 | Q00975 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 25477 | Q00975 | Espacenet |
| US 11795509 B2 | 2023-10-24 | 4 | Q00975 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 25477 | Q00975 | Espacenet |
1 to 10 of 43
See all 43 patentsDrugs18
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ATAGABALIN | CHEMBL593430 | Voltage-gated calcium channel modulator | MODULATOR | ChEMBL |
| BEPRIDIL | CHEMBL1008 | Voltage-gated calcium channel blocker | BLOCKER | ChEMBL |
| BEPRIDIL HYDROCHLORIDE | CHEMBL1200382 | Voltage-gated calcium channel blocker | BLOCKER | ChEMBL |
| CNV2197944 | CHEMBL5314401 | Voltage-gated N-type calcium channel alpha-1B subunit blocker | BLOCKER | ChEMBL |
| ELPETRIGINE | CHEMBL29919 | Voltage-gated N-type calcium channel alpha-1B subunit blocker | BLOCKER | ChEMBL |
| GABAPENTIN | CHEMBL940 | Voltage-gated calcium channel modulator | MODULATOR | ChEMBL |
| GABAPENTIN ENACARBIL | CHEMBL1628502 | Voltage-gated calcium channel modulator | MODULATOR | ChEMBL |
| IMAGABALIN | CHEMBL2103836 | Voltage-gated calcium channel modulator | MODULATOR | ChEMBL |
| LEVETIRACETAM | CHEMBL1286 | Voltage-gated N-type calcium channel alpha-1B subunit blocker | BLOCKER | ChEMBL |
| PHLOROGLUCINOL | CHEMBL473159 | Voltage-gated calcium channel blocker | BLOCKER | ChEMBL |
1 to 10 of 18
See all 18 drugsTrials512
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07606638 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07598474 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07490769 | LEVETIRACETAM | PHASE3 | ClinicalTrials.gov | |
| NCT07477431 | LEVETIRACETAM | PHASE2 | ClinicalTrials.gov | |
| NCT07429734 | GABAPENTIN | PHASE3 | ClinicalTrials.gov | |
| NCT07422233 | LEVETIRACETAM | PHASE4 | ClinicalTrials.gov | |
| NCT07401433 | LEVETIRACETAM | ClinicalTrials.gov | ||
| NCT07382921 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07344467 | PREGABALIN | ClinicalTrials.gov | ||
| NCT07230197 | PREGABALIN | ClinicalTrials.gov |
1 to 10 of 512
See all 512 trialsNIH grants1,284
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CACNA1B papers | Newest fiscal year |
|---|---|---|---|
| P30CA054174 | Mays Cancer Center at UT Health SA | 21 | 2025 |
| R01NS055251 | Voltage-Gated Calcium Channels in Nociceptors and Mechanoreceptors | 18 | 2025 |
| R01HL121253 | L-type channel trafficking and modulation in heart | 7 | 2025 |
| P30CA013696 | Cancer Center Support Grant | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
| R01EY026817 | Calcium channels in retinal photoreceptors | 4 | 2025 |
| ZIANS003164 | Readout of the tubulin code by cellular effectors | 4 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 3 | 2025 |
| P30DK020593 | Vanderbilt Diabetes Research Center | 3 | 2025 |
| R01HL165259 | Central role of Caspase-8 in control of host tolerance and resistance mechanisms in pulmonary macrophage populations during severe respiratory infections | 3 | 2025 |
1 to 10 of 1,284Source NIH's project files
See all 1,284 nih grantsPapers1,947
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting Lung Cancer Stem Cells with Trimebutine: Synergistic Antitumor Activity in Combination with Cisplatin. | Int J Mol Sci | 2026 | 42794641 | PubTator, text mining | PubMed |
| Macro-Micro structural integration for characterizing severity-related structural alterations in mild cognitive impairment. | Neuroimage Clin | 2026 | 42771911 | PubTator, text mining | PubMed |
| Correction to "The Transmitter Release-Site CaV2.2 Channel Cluster is Linked to an Endocytosis Coat Protein Complex". | Eur J Neurosci | 2026 | 42689417 | PubTator, text mining | PubMed |
| Structural rigidity of the I-II loop couples CaV β anchoring to CaV2.2 gating modes. | Proc Natl Acad Sci U S A | 2026 | 42485390 | PubTator, text mining | PubMed |
| A human-derived Pseudorabies virus isolate induces Cav2.2-sensitive Ca2+ influx and JNK-associated retinal epithelial injury. | Microbiol Spectr | 2026 | 42461027 | PubTator, text mining | PubMed |
| Synaptic Ca2+ channels and neurexins are linked through direct and indirect binding complexes. | Sci Rep | 2026 | 42457853 | PubTator, text mining | PubMed |
| Pharmacological Inhibition of Cav2.2 Channels by Recombinant Phα1β Toxin (CTK01512-2). | Basic Clin Pharmacol Toxicol | 2026 | 42383434 | PubTator, text mining | PubMed |
| Targeting Cav2.2 channels for pain management: challenges, innovations, and future perspectives. | Biochem Pharmacol | 2026 | 42361918 | PubTator, text mining | PubMed |
| Disruption of dopamine transmission by cholesterol depletion is associated with alterations in protein lipid raft partitioning and actin dynamics. | Neuropharmacology | 2026 | 42288194 | PubTator, text mining | PubMed |
| Nociceptor-enriched CAPS1 isoform couples to CaV2.2 channels and underlies inflammatory pain hypersensitivity. | bioRxiv | 2026 | 42244681 | PubTator, text mining | PubMed |
1 to 10 of 1,947
See all 1,947 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/774
GET https://conductscience.org/api/genes/v1/774/patents?page=2